The future of antithrombotic and antiplatelet therapy for ischemic heart disease

American Heart Journal

Volumn 136, Issue 4 II SUPPL., 1998, Pages

  Topol, E J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT;

ANTICOAGULANT THERAPY; DRUG EFFICACY; FIBRINOLYTIC THERAPY; FUTUROLOGY; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0031766202     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1053/hj.1998.v136.93431     Document Type: Article

References (12)

1. M Cohen C Demers EP Gurfinkel AG Turpie GJ Fromell S Goodman for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave coronary Events Study Group (ESSENCE) A comparison of low-molecular weight heparin with unfractionated heparin for unstable coronary artery disease N Engl J Med 337 1997 447 452
2. The Global Utilization of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators A comparison of recombinant hirudin versus heparin for the treatment of acute coronary syndromes N Engl J Med 335 1996 775 782
3. CAPRIE Investigators A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE) Lancet 348 1996 1329 1339
4. EJ Topol Toward a new frontier in myocardial reperfusion therapy Circulation 97 1998 211 218
5. BK Metz HD White CB Granger for the GUSTO IIb Investigators A randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO IIb trial J Am Coll Cardiol 31 1998 1493 1498
6. JA Bittl J Strony JA Brinker Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or post-infarction angina. Hirulog Angioplasty Study Investigators N Engl J Med 333 1995 764 769
7. P Theroux Platelet Receptor Inhibition for Ischemic Syndrome Management Study (PRISM) Plus Presented at the American College of Cardiology, Anaheim, Calif March, 1997
8. JG Peterson MA Lauer S Sapp RA Harrington RM Califf EJ Topol Heparin use is required for clinical benefit of GP IIb/IIIa inhibitor eptifibatide in acute coronary syndromes: insights from the PURSUIT Trial Abstract presentation to the American Heart Association, November, 1998 Circulation 98 Suppl I 1998 In press
9. The PURSUIT (Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy) Trial Investigators Inhibition of the platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndrome N Engl J Med 339 1998 436 443
10. C Cannon C McCabe S Borzak for the TIMI 12 Investigators Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial Circulation 97 1998 340 349
11. DA Vorchheimer V Fuster Oral platelet glycoprotein IIb/IIIa receptor antagonists: the present challenge is safety Circulation 97 1998 312 314
12. FA Nicolini P Lee G Rios K Kottke-Marchant EJ Topol Combination of platelet fibrinogen receptor antagonist and direct antithrombin inhibitor at low doses markedly improves thrombolysis Circulation 89 1994 1802 1809